• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Control of Crystallization and Crystal Growth of Drug by Cyclodextrin Complexation

Research Project

Project/Area Number 12672090
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Physical pharmacy
Research InstitutionKumamoto University

Principal Investigator

HIRAYAMA Fumitoshi  Kumamoto University, Faculty of Pharmaceutical Sciences, Pharmaceutics, Associated Professor, 薬学部, 助教授 (90094036)

Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2001: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2000: ¥2,700,000 (Direct Cost: ¥2,700,000)
KeywordsCyclodextrin / Tolbutamide / Chlorpropamide / Amorphous complex / Polymorphism / Crystallization / Crystal growth / Crystal engineering
Research Abstract

Oral hypoglycemic agents such as tolbutamide and chlorpropamide are known to have low solubility in water, and their solubility significantly changes upon polymorphic transitions. In the study, the effects of amorphous 2-hydoxypropyl-cyclodextrins (HP-α-CyD and HP-β-CyD) on the crystallization and crystal growth of these drugs were investigated. The results obtained are summarized as follows :
1. Tolbutamide formed the inclusion complexes with HP-CyDs in a molar ratio of 2 : 1 (host : guest), where HP-α-CyD with a small cavity included preferably the butyl moiety of the drug, whereas HP-β-CyD with a large cavity included the phenyl moiety. On the other hand, chlorpropamide formed the inclusion complex with HP-β-CyD in a molar ratio of 1 : 1, where the chlorbenzene moiety was preferably included in the cavity.
2. The amorphous inclusion complexes of tolbutamide with HP-CyDs were prepared by the spray-drying method. On storage, amorphous tolbutamide in the HP-α-CyD complex crystallized to … More the stable form (Form I). In contrast, the drug in the HP-β-CyD complex crystallized to a metastable form (Form II). Form II in the HP-β-CyD matrix was stable arid hardly converted to Form I crystals for longer storage.
3. The amorphous inclusion complex of chlorpropamide with HP-β-CyD was prepared by the spray-drying method. The complex was hardly subject to polymorphic transition even-under higher pressure. On long storage under high temperature and humidity, the amorphous chlorpropamide in the complex crystallized to a metastable form (Form C), but there was no further transition of Form C to the stable form (Form A) in the HP-β-CyD matrix. The dissolution rate of the complex was much faster than those of Form A and Form C.
In conclusion, HP-CyDs were useful for converting crystalline drug to amorphous complexes and for controlling the crystallization, crystal growth and polymorphic transition. The present results may provide useful information for application of the inclusion complexation of CyDs to crystal engineering. Less

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (23 results)

All Other

All Publications (23 results)

  • [Publications] F.Hirayama: "2-ヒドロキシプロピル-β-シクロデキストリン包接による薬物の結晶化ならびに多形転移の制御"Pharm Tech Japan. 18・5(印刷中). (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M.Anibarro: "Effect of Peracylation of β-Cyclodextrin on the Molecular Structure and on the Formation of Inclusion Complexes : An X-ray Study"J. Am. Chem. Soc.. 123・48. 11854-11862 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F.Hirayama: "Transparent, Adhesive Film Formation of Per-O-valeryl-β-cyc1odextrin"Chem. Lett.. 636-637 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F.Hirayama: "X-ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior"Eur. J. Pharm. Sci.. 11・2-3. 81-88 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K.Kimura: "Effects of Aging on Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide/2-Hydroxypropyl-β-cyclodextrin Complex"Chem. Pharm. Bull.. 48・5. 646-650 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K.Harata: "Crystal Structures of Heptakis (2,6-di-O-ethyl) cyclomaltoheptaose [Heptakis-(2,6-di-O-ethyl)-β-cyclodextrin]. Solvent-regulated Helical Assembly of Macrocycles"Carbohydr. Res.. 392. 597-607 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F. Hirayama, K Kimura, K. Uekama: "Control of Crystallization and Polymorphic Transition of Drugs by Inclusion Complexation with 2-Hydroxypropyl-β-cycldextrin"Pharm Tech Japan. 18(5) (in press). (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M. Anibarro, K. Gessler, L. Uson, G. M. Sheldrick, K. Harata, K, Uekama, F. Hirayama, Y. Abe, W. Saenger: "Effect of Peracylation of β-Cyclodextrin on the Molecular Structure and on the Formation of Inclusion Complexes : An X-ray Study"J. Am. Chem. Soc.. 123(48). 11854-11862 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F. Hirayama, K Zaoh, K Harata, W. Saenger, K Uekama: "Transparent, Adhesive Film Formation of Per-O-valeryl-β-cycledextrin"Chem. Lett.. 636-637 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F. Hirayama, M. Honji, H. Arima, K Okimoto, K. Uekama: "X-ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior"Eur. J. Pham. Sci.. 11(2-3). 81-88 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K. Kimura, F. Hirayama, H. Arima, K. Uekama: "Effects of Aging on Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide / 2-Hydroxypropyl-β-cyclodextrin Complex"Chem. Pharm. Bull.. 48(5). 646-650 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K. Harata, F. Hirayama, K. Uekama: "Crystal Structures of Heptakis (2, 6-di-O-ethyl) -cyclomaltohcptaose [Heptakis (2, 6-di-O-ethyl) -β-cyclodextrin]. Solvent-regulated Helical Assembly of Macrocycles"Carbohydr. Res.. 329(2). 597-607 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] F.Hirayama: "2-ヒドロキシプロピル-β-シクロデキストリン包接による薬物の結晶化ならびに多形転移の制御"Pharm Tech Japan. 18・5(印刷中). (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] H.Yano: "Colon-specific Delivery of Prednisolone-appended α-Cyclodextrin Conjugate : Alleviation of Systemic Side Effect after Oral Administration"J. Controlled Release. 79・1-3. 103-112 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] M.Anibarro: "Effect of Peracylation of β-Cyclodextrin on the Moleular Structure and on the Formation of Inclusion Complexes : An X-ray Study"J. Am. Chem. Soc. 123・48. 11854-11862 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] F.Hirayama: "Transparent, Adhesive Film Formation of Per-O-valeryl-β-cyclodextrin"Chem. Lett. 636-637 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] K.Uekama: "Stabilization and Solubilization Effects of Sulfobutyl Ether β-Cyclodextrin on Prostaglandin E_1 Analogue"Pharm. Res. 18・11. 1578-1585 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] F.Hirayama: "X-Ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior"Eur. J. Pharm. Sci. 11・2-3. 81-88 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] F.Hirayama: "X-ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior"Eur.J.Pharm.Sci.. 11(2-3). 81-88 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] K.Kimura: "Effects of Aging on Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide/2-Hydroxypropyl-β-cyclodextrin Complex"Chem.Pharm.Bull.. 48(5). 646-650 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] K.Harata: "Crystal Structures of Heptakis(2,6-di-O-ethyl) cyclomaltoheptaose [Heptakis(2,6-di-O-ethyl)-β-cyclodextrin].Solvent-regulated Hellcal Assembly of Macrocycles"Carbohydr.Res.. 329(2). 597-607 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] K.Kimura: "Solid-state ^<13>C Nuclear Magnetic Resonance Spectroscopic Study on Amorphous Solid Complexes of Tolbutamide with 2-Hydroxypropyl-α-and-β-cyclodextrins"Pharm.Res.. 16(11). 1729-1734 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] K.Kimura: "Characterization of Tolbutamide Polymorphs (Burger's Forms II and IV) and Polymorphic Transition Behavior"J.Pharm.Sci.. 88(4). 385-391 (1999)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi